SCHEMBL14873232

SCHEMBL14873232

CNC(=O)CC(=O)Nc1cccnc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
LMNA P02545 1/20 0.60
POLB P06746 1/20 0.60
HDAC3 O15379 2/20 0.57
HDAC4 P56524 2/20 0.57
HDAC1 Q13547 2/20 0.57
HDAC7 Q8WUI4 2/20 0.57
HDAC2 Q92769 2/20 0.57
HDAC10 Q969S8 2/20 0.57
HDAC11 Q96DB2 2/20 0.57
HDAC8 Q9BY41 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
HDAC9 Q9UKV0 2/20 0.57
HDAC5 Q9UQL6 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPK1 P28482 1/20 0.57
NOTUM Q6P988 7/20 0.56
RECQL P46063 1/20 0.56
NPC1 O15118 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5142691 0.91 ALDH1A1 (0.73) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL19027207 0.87 ALDH1A1 (0.60) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL11036486 0.85 ALDH1A1 (0.65) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL13592579 0.84 LMNA (0.79) LMNAPOLBHDAC3HDAC4HDAC1
SCHEMBL2605739 0.84 LMNA (0.61) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL17968065 0.83 NOTUM (0.63) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL307606 0.83 ALDH1A1 (0.71) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL1723391 0.83 SMN1; SMN2 (0.78) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL14817538 0.83 ALDH1A1 (0.58) ALDH1A1L3MBTL1LMNAPOLBHDAC3
SCHEMBL30633570 0.81 RAB9A (0.68) ALDH1A1L3MBTL1LMNANPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183254-B1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2017-06-21 EP disclosed
EP-2426108-B1 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC (CA) 2016-08-10 EP disclosed
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 US disclosed
US-20130096088-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET ALDH1A1 3139/4885L3MBTL1 3690/4885LMNA 4752/4885
US-20130096088-A1 Inhibitors of Protein Tyrosine Kinase Activity KDR, FLT1, FLT4 ALDH1A1 4375/4885L3MBTL1 2319/4885LMNA 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.